跳至主要内容
临床试验/ACTRN12620000676910
ACTRN12620000676910尚未招募1 期

Allogeneic Amniotic Epithelial Cells for the Treatment of COVID-19 related respiratory failure, a pilot feasibility randomised controlled trial

Monash Health0 个研究点目标入组 40 人开始时间: 2020年6月15日最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
发起方
Monash Health
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • Patients included in this study must satisfy ALL of the following criteria:
  • Proven or highly suspected COVID-19 through a polymerase chain reaction (PCR) test of a nasal swab; or a negative PCR test with typical radiological finding or CT scan in the absence of alternate diagnoses; or patients with respiratory failure of infective origin admitted to ICU during the COVID-19 pandemic
  • Receiving supplemental oxygen, due to respiratory failure, with PaO2/FiO2 ratio less than or equal to 200 (moderate to severe) or an SaO2 < 92% while receiving more than or equal to 4 litres of O2 via face mask.

排除标准

  • Patients will be excluded if they have ANY of the following:
  • Less than 18 years old
  • Have been intubated for more than 48 hours,
  • Documented significant chronic obstructive airway disease
  • Death is imminent and inevitable within 24 hours,
  • Limitation of therapy includes no invasive mechanical ventilation,
  • Severe global left ventricular dysfunction with an ejection fraction of <25%,
  • Receiving extracorporeal support or is highly likely within the next 12 hours,
  • Acute fulminant hepatitis

研究者

发起方
Monash Health

相似试验